User experiences slow hair regrowth despite using finasteride, topical minoxidil, and supplements like biotin, zinc, and collagen. They seek advice on addressing overall slow hair regrowth.
The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.
A woman experiencing severe hair loss since age 20 is seeking advice on hair transplants for women. Minoxidil hasn't worked for her, and she's considering shaving her head or getting a wig.
The user has been using a combination of finasteride/dutasteride, minoxidil, tretinoin, and hydrocortisone with microneedling and ketoconazole shampoo for hair loss. They are asking if the baby hairs growing will turn into terminal hairs with continued treatment.
Potential success with the hair loss treatment Pyrilutamide, and possible group buying opportunities for it along with other treatments such as Finasteride and Minoxidil.
The user experienced reduced hairfall after taking multivitamins, biotin pills, eating fruit, and drinking coffee. They are concerned about the lack of hair regrowth and seek advice on whether their hair will be alright.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions an update on Dr. Bloxham's Verteporfin treatment.
A discussion on the use of Verteporfin as a hair restoration treatment and whether there are any other doctors or clinics using it currently, aside from Dr. Barghouthi. Treatments such as Minoxidil, Finasteride and RU58841 were also mentioned.
A 25-year-old male is concerned about his blood test results, particularly the low percentage of free testosterone, and is questioning whether starting finasteride for hair loss might worsen this issue. He also notes a slight vitamin D deficiency and lack of sleep before the test.
New hair loss treatments like Shiseido/Replicel and Histogen were discussed, with cautious optimism about their availability by 2018. Setipiprant, Replicel, and Bimatoprost were mentioned as potential treatments expected around 2016-2017.